Media Release Expanding INSIGHT-003 trial evaluating efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy to 50 patientsExpansion based on…
Apollomics’ Class A ordinary shares and public warrants are expected to begin trading today on the Nasdaq Capital Market under the…
Financial Profile Improved Markedly with Global License Agreement to Develop and Commercialize Nyxol for All Three Indications with Cash Runway…
No quantifiable VYN201 plasma concentrations above the assay lower limit of quantification supports “soft” drug approach for topical pan-BD BET…
BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and…
Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc.…
CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the…
Industry leader brings more than 25 years of scientific leadership and expertise in T-cell therapy developmentHOUSTON, March 30, 2023 (GLOBE…
- Additional evidence of durable anti-cancer activity with MDNA11 monotherapy seen in latest radiographic scans from first four dose escalation cohorts…
– Initiated registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational study – – First subject…